These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12856057)

  • 1. Hunter-gatherers win profit-sharing deal for obesity drug.
    Wise J
    Bull World Health Organ; 2003; 81(5):382. PubMed ID: 12856057
    [No Abstract]   [Full Text] [Related]  

  • 2. Obesity: the fat lady sings?
    Cairns E
    Drug Discov Today; 2005 Mar; 10(5):305-7. PubMed ID: 15749277
    [No Abstract]   [Full Text] [Related]  

  • 3. Heavy meddling.
    Reno J; Leland J
    Newsweek; 1999 Oct; 134(16):56-7, 59. PubMed ID: 10622865
    [No Abstract]   [Full Text] [Related]  

  • 4. In search of fat profits.
    Watts G
    BMJ; 2007 Jun; 334(7607):1298-9. PubMed ID: 17585156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmaceutical market for obesity therapies.
    Wong D; Sullivan K; Heap G
    Nat Rev Drug Discov; 2012 Sep; 11(9):669-70. PubMed ID: 22935797
    [No Abstract]   [Full Text] [Related]  

  • 6. Lifestyle drug market booming.
    Atkinson T
    Nat Med; 2002 Sep; 8(9):909. PubMed ID: 12205440
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug therapy of obesity will come later].
    Falkenberg M
    Lakartidningen; 1999 May; 96(21):2582-3. PubMed ID: 10388276
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes and obesity: the twin epidemics.
    Smyth S; Heron A
    Nat Med; 2006 Jan; 12(1):75-80. PubMed ID: 16397575
    [No Abstract]   [Full Text] [Related]  

  • 9. Happier, hornier, hairier.
    Nat Biotechnol; 2003 Jan; 21(1):1. PubMed ID: 12511892
    [No Abstract]   [Full Text] [Related]  

  • 10. Opportunities and challenges for the development of pharmacological therapies for obesity treatment.
    Cawthorne MA
    Obes Rev; 2007 Mar; 8 Suppl 1():131-6. PubMed ID: 17316316
    [No Abstract]   [Full Text] [Related]  

  • 11. First in class, best in class or a wild card: who will dominate the anti-obesity medication market?
    Collins E; Beattie A; Ramagopalan SV; Pearson-Stuttard J
    J Comp Eff Res; 2024 Jul; 13(7):e240044. PubMed ID: 38808628
    [No Abstract]   [Full Text] [Related]  

  • 12. A big issue?
    Marnell T
    Br J Gen Pract; 2006 Jan; 56(522):57. PubMed ID: 16438818
    [No Abstract]   [Full Text] [Related]  

  • 13. National trends in the use and costs of anti-obesity medications in England 1998-2005.
    Srishanmuganathan J; Patel H; Car J; Majeed A
    J Public Health (Oxf); 2007 Jun; 29(2):199-202. PubMed ID: 17494061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newsmaker: Zafgen.
    Rohn J
    Nat Biotechnol; 2011 Dec; 29(12):1068. PubMed ID: 22158352
    [No Abstract]   [Full Text] [Related]  

  • 15. Obesity market overview.
    Farrigan C; Pang K
    Nat Rev Drug Discov; 2002 Apr; 1(4):257-8. PubMed ID: 12120276
    [No Abstract]   [Full Text] [Related]  

  • 16. Ayurveda.
    Padma TV
    Nature; 2005 Jul; 436(7050):486. PubMed ID: 16049472
    [No Abstract]   [Full Text] [Related]  

  • 17. HCA efficiency.
    Heymsfield SB; Aronne LJ; Blackburn GL
    Diabetes Obes Metab; 2004 Nov; 6(6):458-9; author reply 460-1. PubMed ID: 15479223
    [No Abstract]   [Full Text] [Related]  

  • 18. Employers, others not sold on new anti-obesity drugs.
    Reinke T
    Manag Care; 2012 Sep; 21(9):33-6. PubMed ID: 23050423
    [No Abstract]   [Full Text] [Related]  

  • 19. Africa finds drug giants guilty of excessive pricing.
    AIDS Policy Law; 2003 Dec; 18(22):5. PubMed ID: 14974397
    [No Abstract]   [Full Text] [Related]  

  • 20. One pill makes you smaller: the demand for anti-obesity drugs.
    Cawley J; Rizzo JA
    Adv Health Econ Health Serv Res; 2007; 17():149-83. PubMed ID: 19548552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.